We showed a trend of significant difference in the overall survival of patients with a methylated MGMT promoter, compared to those with an unmethylated promoter.
← all excerpts
Outcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy.
1
—
—